Introduction
============

This study compared a nasal high-flow oxygen therapy (NHFO~2~) with conventional oxygen therapy via a Venturi mask (VM) or noninvasive ventilation (NIV) in patients with hypoxic respiratory failure. Study endpoints were functional respiratory parameters, dyspnea, patient comfort and a global rating by the patients.

Methods
=======

We included 14 patients with hypoxic respiratory failure (paO~2~\<55 mmHg under room air). Exclusion criteria were ventilatory failure, hemodynamic instability, cardiogenic pulmonary edema, NIV contraindications and inability to cooperate. Patients were treated in a randomized order for 30 minutes each with NHFO~2~(Optiflow^®^; Fisher-Paykel), VM or NIV, using a FiO~2~of 0.6. Every treatment phase was preceded by a 15-minute baseline phase in which the patients received oxygen via a standard nasal prong (SaO~2~goal \>88%). At the end of each treatment phase vital signs and blood gases were measured and patients rated their dyspnea and their general comfort on a 10-point scale. Finally, patients were ask for a global rating of all three devices ranging from 1 (very good) to 6 (failed) and could choose one device for further treatment.

Results
=======

The paO~2~was highest under NIV with 129 ± 38 mmHg, followed by NHFO~2~(101 ± 34 mmHg, *P*\< 0.01 vs. NIV) and VM (85 ± 21 mmHg, *P*\< 0.001 vs. NIV, *P*\< 0.01 vs. NHFO~2~, ANOVA). All other vital and blood gas parameters did not show significant differences. Dyspnea rating on a 10-point Borg scale was significantly better under NHFO~2~(2.9 ± 2.1) and VM (3.3 ± 2.3) compared to NIV (5.0 ± 3.3) (*P*\< 0.05, vs. NHFO~2~or VM). Comfort rating showed similar results: NHFO~2~2.7 ± 1.8; VM 3.1 ± 2.8; NIV 5.4 ± 3.1 (*P*\< 0.05, NIV vs. NHFO~2~or VM). In the final global rating using German school grades from 1 to 6 NHFO~2~also received the best rating (2.3 ± 1.4), followed by VM (3.2 ± 1.7, *P*= NS vs. NHFO~2~) and NIV (4.5 ± 1.7, *P*\< 0.01 vs. NHFO~2~and *P*\< 0.05 vs. VM). For further treatment 10 patients chose NHFO~2~, three VM and one NIV.

Conclusion
==========

NHFO~2~is a promising new device for oxygen supply in respiratory failure, offering better oxygenation than the VM and better patient comfort and tolerance than NIV.
